, , Rosenfeld, M., Wainwright, C. E., Higgins, M., Wang, L. T., McKee, C., Campbell, D., Tian, S., Schneider, J., Cunningham, S., Davies, J. C., Harris, W., Mogayzel, P., McCoy, K., Milla, C., Rubenstein, R., Walker, S., Black, P., Montgomery, G., McColley, S., Hiatt, P., Sawicki, G., Rock, M., Aurora, P., Ratjen, F., Maitra, A., Ives, A., Gaillard, E., McNalley, P., Selvadurai, H., Robinson, P., Rosenfeld, M., Wainwright, C. E., Higgins, M., Wang, L. T., McKee, C., Campbell, D., Tian, S., Schneider, J., Cunningham, S., & Davies, J. C. (2018). ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet, 6(7), 545–553. http://access.bl.uk/ark:/81055/vdc_100066408235.0x000004